BIOV — Biovaxys Technology Share News
0.000.00%
HealthcareSpeculativeMicro CapSucker Stock
- CA$11.25m
- CA$11.13m
BRIEF-Biovaxys Technology Corp - International Patent Application Filed For Cervical Cancer Vaccine
NewsBRIEF-BioVaxys Reports Appointment To Board Of Directors
NewsBRIEF-Biovaxys Announces Bioproduction Of Bvx-1021 For Its Pan-Sarbecovirus Program In Collaboration With Ohio State University
NewsBRIEF-Biovaxys Closes Final Tranche Of Non-Brokered Private Placement
NewsBRIEF-Biovaxys Reports Complete Inhibition Of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein
NewsBRIEF-Biovaxys Technology Corp Files Applications For International Patent And Trademark Protection Of CoviDTH
NewsBRIEF-BioVaxys Files US Patent Application For Pan-Sarbecovirus Vaccine
NewsBRIEF-BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission
NewsBRIEF-Biovaxys Bioproduction Partner Wuxi Biologics Completes Synthesis Of Recombinant Sars-Cov-2 S-Proteins For Bvx-0320 And Covidth Programs
NewsBRIEF-Biovaxys Announces Non-Brokered Private Placement Consisting Of Up To 9,090,909 Units At $0.22 Per Unit
NewsBRIEF-BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development
NewsBRIEF-Biovaxys Technology Files FDA Pre-Ind Meeting Request And Briefing Package For Covid-T
NewsBRIEF-BioVaxys Expands Intellectual Property Portfolio
NewsBRIEF-BioVaxys Enters Agreement With Inotiv For Preclinical Studies Of Its Covid-T Immunodiagnostic Program
NewsBRIEF-BioVaxys Enters Agreement With Wuxi Biologics To Synthesize Proteins For Its SARS-CoV-2 Vaccine
NewsBRIEF-Biovaxys And Bioelpida Sign Term Sheet For Clinical Grade Bvx-0918A Bio-Production
News